secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063702
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics raises FY2023 oncology sales guidance; projects FY2024 EBITDA breakeven
--------------------------------------------------------------------------------

- FY2023 net product sales guidance raised to $123-125M; oncology franchise now $104-106M.
- FY2024 net product sales expected $138-158M; acute care franchise growing >48% YoY.
- Gross margin forecast to improve from 41% (2023) to 69% (2024) and >75% (2025+).
- Q3 2023 inventory write-offs of $7.5M; one-time expenses $4.1M; loss from ops $24.9M.
- ZYNRELEF expanded label PDUFA date Jan 23, 2024; VAN program PAS submission early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/0000950170-23-063702-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023063702/hrtx-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063702

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer